AVTX Avalo Therapeutics, Inc.
Avalo Therapeutics, Inc. (AVTX) is expected to report earnings on February 4, 2027, before the market open. The consensus earnings estimate is a loss of $0.49 per share, and the stock has had a Post-Earnings Announcement Drift (PEAD) of -0.2% since its last earnings release on November 5, 2026.
Sign in or subscribe to unlock sentiment, short interest, and technical indicators.
Whisperings™
About Avalo Therapeutics, Inc.
Avalo Therapeutics Inc. is a clinical-stage precision medicine company which discovers, develops and commercializes targeted therapeutics for patients with significant unmet clinical need in immunology, immuno-oncology and rare genetic diseases. Avalo Therapeutics Inc., formerly known as Cerecor, is based in WAYNE, Pa.
Sector
Healthcare
Industry
Biotechnology
Charts powered in part by Lightweight Charts™ by TradingView.